Created at Source Raw Value Validated value
June 25, 2024, noon usa

1. presence of fever within 3 days before the study vaccination; 2. a history of infection or disease related to severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), or other disease corresponding use of immunosuppressants; 3. a history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema; 4. a medical or family history of seizure, epilepsy, encephalopathy and psychosis; 5. immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including guillain-barre syndrome \[gbs\], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc. 6. long-term use of immunosuppressant therapy or immunomodulatory drugs for ≥14 days within the first six months prior to enrollment. whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed; 7. those who are tested positive for hiv in terms of serology. 8. patients on antituberculosis therapy; 9. presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (skin basal cell carcinoma and carcinoma in-situ of cervix are exceptions and will not be excluded), such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia; 10. contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders; 11. participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study; 12. participants who received other investigational drugs or vaccines within 1 month before the study vaccination; 13. participants who is at the acute state of disease, such as acute onset of chronic heart f ailure, acute sore throat,hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis; 14. participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination; 15. those who donated blood or had blood loss (≥450 ml) within 3 months before the vaccination or plan to donate blood during the study period; 16. those who are pregnant or breast-feeding or plan to be pregnant during the study period; 17. those who plan to donate ovum or sperms during the study period; 18. those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing; 19. those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants.

1. presence of fever within 3 days before the study vaccination; 2. a history of infection or disease related to severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), or other disease corresponding use of immunosuppressants; 3. a history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema; 4. a medical or family history of seizure, epilepsy, encephalopathy and psychosis; 5. immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including guillain-barre syndrome \[gbs\], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc. 6. long-term use of immunosuppressant therapy or immunomodulatory drugs for ≥14 days within the first six months prior to enrollment. whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed; 7. those who are tested positive for hiv in terms of serology. 8. patients on antituberculosis therapy; 9. presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (skin basal cell carcinoma and carcinoma in-situ of cervix are exceptions and will not be excluded), such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia; 10. contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders; 11. participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study; 12. participants who received other investigational drugs or vaccines within 1 month before the study vaccination; 13. participants who is at the acute state of disease, such as acute onset of chronic heart f ailure, acute sore throat,hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis; 14. participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination; 15. those who donated blood or had blood loss (≥450 ml) within 3 months before the vaccination or plan to donate blood during the study period; 16. those who are pregnant or breast-feeding or plan to be pregnant during the study period; 17. those who plan to donate ovum or sperms during the study period; 18. those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing; 19. those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants.

June 21, 2023, 4 p.m. usa

presence of fever within 3 days before the study vaccination; a history of infection or disease related to severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), or other disease corresponding use of immunosuppressants; a history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema; a medical or family history of seizure, epilepsy, encephalopathy and psychosis; immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including guillain-barre syndrome [gbs], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc. long-term use of immunosuppressant therapy or immunomodulatory drugs for ≥14 days within the first six months prior to enrollment. whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed; those who are tested positive for hiv in terms of serology. patients on antituberculosis therapy; presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (skin basal cell carcinoma and carcinoma in-situ of cervix are exceptions and will not be excluded), such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia; contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders; participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study; participants who received other investigational drugs or vaccines within 1 month before the study vaccination; participants who is at the acute state of disease, such as acute onset of chronic heart f ailure, acute sore throat,hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis; participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination; those who donated blood or had blood loss (≥450 ml) within 3 months before the vaccination or plan to donate blood during the study period; those who are pregnant or breast-feeding or plan to be pregnant during the study period; those who plan to donate ovum or sperms during the study period; those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing; those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants.

presence of fever within 3 days before the study vaccination; a history of infection or disease related to severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), or other disease corresponding use of immunosuppressants; a history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema; a medical or family history of seizure, epilepsy, encephalopathy and psychosis; immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including guillain-barre syndrome [gbs], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc. long-term use of immunosuppressant therapy or immunomodulatory drugs for ≥14 days within the first six months prior to enrollment. whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed; those who are tested positive for hiv in terms of serology. patients on antituberculosis therapy; presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (skin basal cell carcinoma and carcinoma in-situ of cervix are exceptions and will not be excluded), such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia; contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders; participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study; participants who received other investigational drugs or vaccines within 1 month before the study vaccination; participants who is at the acute state of disease, such as acute onset of chronic heart f ailure, acute sore throat,hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis; participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination; those who donated blood or had blood loss (≥450 ml) within 3 months before the vaccination or plan to donate blood during the study period; those who are pregnant or breast-feeding or plan to be pregnant during the study period; those who plan to donate ovum or sperms during the study period; those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing; those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants.